Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines
Executive Summary
Genentech will tap expertise of privately-held BioNTech in a collaboration aimed at developing individually tailored vaccines for use against a broad range of cancers, which the duo says offers “a new treatment paradigm” for oncology.
You may also be interested in...
BioNTech Gets Gates Foundation Funding For HIV, TB Drug Discovery
The Bill & Melinda Gates Foundation has invested $55m in an infectious disease collaboration with Germany’s BioNTech that could reach up to $100m in total funding.
Why Roche Oncology Bet Big On Neoantigen-Directed T-Cell Therapy
In an interview at J.P. Morgan, Roche's James Sabry explained why it wants to lead the pack in personalized, neoantigen-directed cellular therapy, after announcing tie-up with Adaptive Biotechnologies.
BioNTech, Neon Take A Step Forward In Personalized Cancer Vaccines
Two studies published in Nature July 5 showed that personalized cancer vaccines from BioNTech and Neon Therapeutics delivered potent immune responses in patients with melanoma. Both companies are moving forward with new studies.